FY2024 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Equities researchers at Leerink Partnrs raised their FY2024 earnings per share estimates for IQVIA in a note issued to investors on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $10.13 per share for the year, up from their previous forecast of $10.07. The consensus estimate for IQVIA's current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA's FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

Several other research firms have also weighed in on IQV. Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They issued a "buy" rating and a $276.00 price objective on the stock. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Robert W. Baird cut their price target on IQVIA from $213.00 to $212.00 and set a "neutral" rating on the stock in a research note on Wednesday. Finally, Truist Financial dropped their price objective on shares of IQVIA from $265.00 to $261.00 and set a "buy" rating for the company in a report on Thursday. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $256.19.

IQVIA Stock Performance

Shares of IQV traded down $1.31 during mid-day trading on Friday, hitting $199.06. 1,135,902 shares of the company's stock were exchanged, compared to its average volume of 1,186,062. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market cap of $36.13 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49. The stock's 50-day simple moving average is $212.86 and its 200-day simple moving average is $224.44. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA in the third quarter valued at about $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the second quarter valued at approximately $29,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA during the second quarter valued at approximately $32,000. Finally, Avior Wealth Management LLC lifted its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.